Recombinant Human CD79B protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2073

---

Validation Data Gallery

• 

  Purity of Recombinant Human CD79B was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human CD79B protein Ala29-Asp159 (Accession# P40259-1) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 974
• Accession: P40259-1
• PredictedSize: 41.5 kDa
• SDS-PAGE: 48-65 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD79 molecule encompasses two transmembrane proteins, CD79a and CD79b, which form a disulfide-linked heterodimer and are members of the immunoglobulin (Ig) gene superfamily. CD79b molecule (also known as B29, IGB, AGM6, and Igbeta) is expressed almost exclusively on B cells and B-cell neoplasms, influencing antigen internalization and increasing antigen presentation efficiency. CD79b mutation could be a key biomarker for DLBCL disease progression.

References:

1. C J van Noesel, et al. (1991) J Immunol. Jun 1;146(11):3881-8.
2. C J Van Noesel, et al. (1992) J Exp Med. Jun 1;175(6):1511-9.
3. J Hombach, et al. (1990) Nature. Feb 22;343(6260):760-2.
4. C Bonnerot, et al. (1995) Immunity. Sep;3(3):335-47.
5. Peng-Peng Xu, et al. (2022) Clin Lymphoma Myeloma Leuk. Dec;22(12):e1051-e1058.e1.